Karolinska Institutet establishes research base in Hong Kong and China after record donation

4 February 2015

Sweden’s Karolinska Institutet is to set up its own research base in Hong Kong. This initiative is made possible by a donation of $50 million, by Hong Kong-based businessman Ming Wai Lau. This is one of the largest private donations ever received by Karolinska Institutet.

The Ming Wai Lau Center for Regenerative Medicine will comprise two nodes, one in Stockholm and one in Hong Kong, and will allow scientists from Hong Kong, China and around the world to work together in an independent research environment under the auspices of Karolinska Institutet.

Research focus of new center

The Center’s research focus will be on three major disease areas in which Karolinska Institutet and several Hong Kong universities possess unique expertise. One of its objectives is to use stem cell technology to rebuild damaged tissue, focusing, for example, on heart tissue damaged by infarction, spinal injury and finding a cure for Parkinson’s disease, and on repairing a damaged liver using stem cell transplants.

“This exceedingly generous donation from Ming Wai presents unprecedented opportunities to do groundbreaking research in these extremely important disease areas,” says Anders Hamsten, Vice Chancellor of Karolinska Institutet, adding: “The new center will provide our university with a pathway to critically important knowledge and bring us closer to key partners.”

“It is with great pleasure and enthusiasm that I support world-leading research into regenerative medicine being done at Karolinska Institutet and the deepening of existing research partnerships between Karolinska Institutet and the top universities in Hong Kong and China,” says Ming Wai Lau.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical